PDCD1 and lung carcinoma: Since the TLR agonist poly (I: C) can enhance the expression of TMPRSS2 and act on innate immune cells, this means that the use of TLR agonists in lung cancer will enhance the efficacy of PD-1 targeting adaptive immune cells (Nakazono et al., 2021).